It’s never too late to start investing. Whether the market is rising or falling, you’ll always find opportunities to buy quality stocks that may deliver big results over the long term. Even if a particular player already has performed well in recent months or years, if it has financial strength and solid future prospects, its stock could continue to gain — so you as an investor might benefit even if you buy later in that company’s story.

With this in mind, if I had to start over with $1,000 in stocks today, I know exactly which ones I would buy. They are each in the healthcare industry: one is a biotech player that I already hold, another is the global robotics surgery leader, and the last one is a pharma and medtech giant. According to the closing prices as of June 17, I could buy one share of each for a total of $1,094. Let’s check them out.

Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a “Double Down” signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same “Total Conviction” signal is flashing for a company 1/100th the size of Nvidia. Continue »

1. Vertex Pharmaceuticals

I’ve owned Vertex Pharmaceuticals (NASDAQ: VRTX) shares for a few years, but if I had to start investing all over, I would buy them again. For two reasons. First, Vertex is the world’s leader in cystic fibrosis (CF) treatment, and its intellectual property ensures its position into the late 2030s. Vertex’s top CF treatment, Trikafta, is a blockbuster, and its more recent launch, Alyftrek, is gaining momentum.

Importantly, Vertex has proven its ability to expand into other treatment areas, having won approval in recent years for a blood disorders treatment and a pain management medicine. These drugs contributed 25% to growth in the recent quarter.

Vertex has promising candidates in the pipeline, including povetacicept, which may treat several diseases including kidney disease IgA nephropathy. That particular candidate is in a phase 3 trial. The biotech’s strong ongoing CF earnings engine and this expansion into other areas suggest a bright future — making it a stock I would invest in all over again.

2. Intuitive Surgical

Intuitive Surgical (NASDAQ: ISRG) is the global leader in robotic surgery, and it has a fantastic moat, or competitive advantage. This makes it a company that’s likely to continue generating growth well into the future.

Intuitive Surgical’s moat has two parts: First, surgeons generally train on the company’s flagship Da Vinci robot, so they might favor using that robot and its latest updates throughout their careers. Second, surgical robots are major investments, topping $1 million, so hospitals probably will stick with this investment for quite some time to amortize it. All of this is good news for Intuitive Surgical.

I also like the fact that this medical device company’s revenue opportunity doesn’t end with the sale or leasing out of a robot. The customer must spend on service contracts and instruments and accessories, generating recurrent revenue for Intuitive Surgical. In fact, instruments and accessories revenue makes up a greater share of revenue than the actual sale of robotic systems. All of this makes the stock a fantastic long-term investment to buy at any time.

3. Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a pharma giant, with business spanning two distinct areas: pharmaceuticals, which J&J calls its innovative medicine division, and medtech. In the first quarter of the year, revenue increased nearly 10%, which is a huge feat for a healthcare giant. And the growth may not stop there. The company says it’s on its way to reach its goals of $100 billion in revenue this year and double-digit growth by the end of the decade.

It’s clear J&J has the tools to power this momentum. The company has 28 programs or platforms that deliver $1 billion or more in annual revenue. And 10 brands in the innovative medicine unit are generating double-digit growth. J&J’s acquisitions in recent years — such as heart recovery company Abiomed — also are bearing fruit, adding to strengths in the medtech business.

Finally, J&J is committed to dividend growth — it’s a Dividend King — and recently lifted its dividend for the 64th year. The company’s focus on and delivery of earnings growth, as well as this dividend track record, make it a stock I’d absolutely buy if I were getting started in investing today.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

• Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $547,138!*

• Apple: if you invested $1,000 when we doubled down in 2008, you’d have $56,799!*

• Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $417,305!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, available when you join Stock Advisor, and there may not be another chance like this anytime soon.

See the 3 stocks »

*Stock Advisor returns as of June 9, 2026

Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Intuitive Surgical and Vertex Pharmaceuticals. The Motley Fool recommends Johnson & Johnson and recommends the following options: long January 2028 $520 calls on Intuitive Surgical and short January 2028 $530 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

If I Had to Start Over With $1,000 in Stocks Today, Here’s Exactly What I’d Buy was originally published by The Motley Fool